Acro Biomedical Co., Ltd. (ACBM) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2020

Acro Biomedical Co., Ltd.

CIK: 1622996 Ticker: ACBM
Document And Entity Information - USD ($)
12 Months Ended
Dec. 31, 2020
Mar. 29, 2021
Jun. 30, 2020
Document And Entity Information [Abstract]   
Entity Registrant NameACRO BIOMEDICAL CO., LTD.  
Entity Central Index Key0001622996  
Entity Current Reporting StatusYes  
Current Fiscal Year End Date--12-31  
Entity Filer CategoryNon-accelerated Filer  
Entity Common Stock, Shares Outstanding 47,760,000 
Entity Public Float  $ 44,400,000
Entity Well-known Seasoned IssuerNo  
Document Type10-K  
Document Period End DateDec. 31, 2020  
Amendment Flagfalse  
Document Fiscal Year Focus2020  
Document Fiscal Period FocusFY  
Entity Voluntary FilersNo  
Entity Small Businesstrue  
Entity Emerging Growth Companytrue  
Entity Shell Companyfalse  
Entity Interactive Data CurrentYes  
Entity Ex Transition Periodfalse  

View differences made from one year to another to evaluate Acro Biomedical Co., Ltd.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Acro Biomedical Co., Ltd..


Assess how Acro Biomedical Co., Ltd.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Acro Biomedical Co., Ltd.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools